EMA validates Gilead Sciences ’ marketing application for BIC/FTC/TAF combination

US biopharmaceutical company Gilead Sciences ’ marketing authorisation application (MAA) for a fixed-dose drug combination to treat HIV-1 infection in adults has been fully validated and is currently under evaluation by the European Medicines Agency (…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news